CEYEBER Develops First-Ever Intraocular Smart Lens: The Third Eye

The CEYEBER Third Eye™ is the next leap in smart intraocular lens technologies. Developed by reputable lifestyle healthcare company Strathspey Crown, the product features technology protected by U.S. Patent No. 9,662,199. The company has a strong IP portfolio and has amassed many U.S. patents within the healthcare, energy and technology industries.

Over the last couple of decades, we’ve seen the introduction of consumer technology that has transformed the capacity for human connection, health, and productivity. Now, we’re on the brink of yet another

game-changing shift. CEYEBER’s patented smart lens technology includes:

  • An implantable intraocular lens with an optic
  • A camera and an LED display
  • A communications module that wirelessly transmits and receives information

As recent as November 29, 2022, Strathspey Crown has also been granted 2 new patents: US Patent No. 11,514, 616 covering a system providing augmented reality to a person disposed in a real-world, physical environment where a camera is configured to capture real world images; and US Patent No. 11,516,392 covers an implantable system with a camera where an analytical engine analyzes the images to determine whether any objects or aspect of the captured image is considered an unviewable element.

The CEYEBER Third Eye™ is an intraocular lens and a revolutionary solution for macular degeneration and preventing blindness. This has the potential to significantly reduce the prevalence of global blindness and visual impairment.

In cases of macular degeneration, optical signals cannot reach the brain as they should. By placing CEYEBER’s high-resolution, finely pixelated display in the eye, doctors may be able to help those with significant degeneration regain a crucial amount of sight.

“The CEYEBER intraocular lens technology promises to significantly advance the way we perceive and interact with the world,” said Dr. Richard Lindstrom, Board Member, CEYEBER.

The CEYEBER Third Eye™ will be released once it has been approved and deemed safe by the FDA. Ultimately, the founder Robert Edward Grant (in tandem with Strathspey Crown) aims to develop groundbreaking smart implantables that integrate cellular, Bluetooth and WIFI transmission in an elegant cognitive interface.

“We’re very excited about our revolutionary solution for age related macular degeneration (AMD), accommodative vision correction and the long-term prevention of blindness. According to recent estimates, close to 200 million people globally are affected by AMD which is expected to grow to 288 million people by 2040. CEYEBER will have a profound impact on the quality of life and vision for millions of people worldwide,” explained Robert Edward Grant, Founder and CEO of CEYEBER.

Over the last decade, Mr. Robert Grant has established himself as a transformational leader in encryption, personal data sovereignty, ophthalmic surgery, and medical technology advancement. Grant brings years of experience to the field, having served as:

  • Founder, Chairman, and Managing Partner of Strathspey Crown Holdings
  • Founder and Board Member of AEON Biopharma Inc.
  • Co-Founder and Board Member of Alphaeon Credit
  • CEO and President of Bausch and Lomb Surgical
  • President of Allergan Medical
  • Chairman, CEO, and President of Biolase Technology

Together, Grant and the other members of the CEYEBER Advisory Board are providing expert guidance and real-world experience to shape the brand’s mission. This team of highly renowned ophthalmologists, eye surgeons, and medical directors has big plans for the future of intraocular smart lenses.

SourceCEYEBER

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”